Journal article
Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy.
- Petrausch U Department of Oncology, University Hospital Zurich.
- Samaras P Department of Oncology, University Hospital Zurich.
- Haile SR Biostatistics Unit, Institute of Social and Preventive Medicine, University of Zurich.
- Veit-Haibach P Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Zürich, Switzerland.
- Soyka JD Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Zürich, Switzerland.
- Knuth A Department of Oncology, University Hospital Zurich.
- Hany TF Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Zürich, Switzerland.
- Mischo A Department of Oncology, University Hospital Zurich.
- Renner C Department of Oncology, University Hospital Zurich.
- Schäefer NG Department of Oncology, University Hospital Zurich; Division of Nuclear Medicine, Department of Medical Radiology, University Hospital Zurich, Zürich, Switzerland. Electronic address: niklaus.schaefer@usz.ch.
- 2010-02-09
Published in:
- Annals of oncology : official journal of the European Society for Medical Oncology. - 2010
Antineoplastic Agents
Fluorodeoxyglucose F18
Humans
Lymphoma, Large B-Cell, Diffuse
Positron-Emission Tomography
Risk Factors
Tomography, X-Ray Computed
English
BACKGROUND
The purpose of this study was to evaluate the impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) during follow-up of patients with diffuse large B-cell lymphoma (DLBCL) being in complete remission or unconfirmed complete remission after first-line therapy.
PATIENTS AND METHODS
DLBCL patients receiving FDG-PET/CT during follow-up were analyzed retrospectively. Confirmatory biopsy was mandatory in cases of suspected disease recurrence.
RESULTS
Seventy-five patients were analyzed and 23 (30%) had disease recurrence. The positive predictive value (PPV) of FDG-PET/CT was 0.85. Patients >60 years [P = 0.036, hazard ratio (HR) = 3.82, 95% confidence interval (CI) 1.02-7.77] and patients with symptoms indicative of a relapse (P = 0.015; HR = 4.1; 95% CI 1.20-14.03) had a significantly higher risk for relapse. A risk score on the basis of signs of relapse, age >60 years, or a combination of these factors identified patients at high risk for recurrence (P = 0.041).
CONCLUSIONS
FDG-PET/CT detects recurrent DLBCL after first-line therapy with high PPV. However, it should not be used routinely and if only in selected high-risk patients to reduce radiation burden and costs. On the basis of our retrospective data, FDG-PET/CT during follow-up is indicated for patients <60 years with clinical signs of relapse and in patients >60 years with and without clinical signs of relapse.
The purpose of this study was to evaluate the impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) during follow-up of patients with diffuse large B-cell lymphoma (DLBCL) being in complete remission or unconfirmed complete remission after first-line therapy.
PATIENTS AND METHODS
DLBCL patients receiving FDG-PET/CT during follow-up were analyzed retrospectively. Confirmatory biopsy was mandatory in cases of suspected disease recurrence.
RESULTS
Seventy-five patients were analyzed and 23 (30%) had disease recurrence. The positive predictive value (PPV) of FDG-PET/CT was 0.85. Patients >60 years [P = 0.036, hazard ratio (HR) = 3.82, 95% confidence interval (CI) 1.02-7.77] and patients with symptoms indicative of a relapse (P = 0.015; HR = 4.1; 95% CI 1.20-14.03) had a significantly higher risk for relapse. A risk score on the basis of signs of relapse, age >60 years, or a combination of these factors identified patients at high risk for recurrence (P = 0.041).
CONCLUSIONS
FDG-PET/CT detects recurrent DLBCL after first-line therapy with high PPV. However, it should not be used routinely and if only in selected high-risk patients to reduce radiation burden and costs. On the basis of our retrospective data, FDG-PET/CT during follow-up is indicated for patients <60 years with clinical signs of relapse and in patients >60 years with and without clinical signs of relapse.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1093/annonc/mdq015
- PMID 20139151
- Persistent URL
- https://sonar.ch/global/documents/135224
Statistics
Document views: 4
File downloads: